

## シンポジウム

## 新世代のがん分子標的療法開発戦略シンポジウム

- シンポジウム世話人代表・実行委員長：吉川 敏一（京都府立医科大学 学長）
- 主 催：新世代のがん分子標的療法開発戦略シンポジウム実行委員会  
京都府公立大学法人京都府立医科大学
- 共 催：独立行政法人国立がん研究センター\*  
一般社団法人ARO協議会  
公益財団法人 先端医療振興財団
- 後 援：文部科学省，厚生労働省，日本医師会，京都府  
NPO 法人キャンサーネットジャパン  
(2014年12月6日(土) 於：国立京都国際会館 大会議場)

Consolidated Strategic Meeting on Development  
of Next-generation Cancer Molecular-targeted Therapy

- Chairman of Organizing Committee & Steering Committee :  
Toshikazu Yoshikawa (President, Kyoto Prefectural University of Medicine)
- Organized by : Organizing Committee of the Consolidated Strategic Meeting on Development of Next-generation  
Cancer Molecular-targeted Therapy  
Kyoto Prefectural University of Medicine
- Co-organized by : National Cancer Center  
ARO Council  
Foundation for Biomedical Research and Innovation
- Supported by : Ministry of Education, Culture, Sports, Science and Technology  
Ministry of Health, Labour and Welfare  
Japan Medical Association  
Kyoto Prefecture  
CancerNet Japan, NPO  
(Saturday, December 6, 2015 Kyoto International Conference Center, Japan)

**Abstract**

Drug discovery in the academic sector in Japan is not falling behind the US and EU in any way. To name one example, four great discoveries of molecular-targeted anti-cancer drugs which have originated in our academic sector during the past decade are significantly revolutionizing not only clinical practice in oncology, but also tumor biology itself.

However, if we focus on the clinical development of such four drugs, global big pharma has taken over those initiatives, except one. The reason is clear: the lack of clinical science realization and consolidated global strategy among the industrial sector in Japan.

We therefore organized a consolidated strategic meeting, inviting distinguished Japanese researchers who contribute to the research and development for internationally recognized molecular-targeted drugs. Lectures on the innovative research and clinical practice in oncology were presented at this valuable meeting.

We should review and realize once again the responsibility and mission of academia which assumes a vital role in the life science innovation in Japan.

**Key words**

drug discovery, cancer molecular-targeted drugs, academic-industrial collaboration, Japan Cancer Research Project, Japan Agency for Medical Research and Development (AMED)

*Rinsho Hyoka (Clinical Evaluation)*. 2015 ; 43 : 59-144.

\* 2015年4月より国立研究開発法人国立がん研究センター